Compare Invesco DB Agriculture Fund (DBA) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Agriculture Fund vs Gilead Sciences, Inc. — how do they compare? Invesco DB Agriculture Fund trades at $28.29 (market cap $1.32B), while Gilead Sciences, Inc. trades at $151.24 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 138.2× Invesco DB Agriculture Fund's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Invesco DB Agriculture Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Agriculture Fund for 24 Days and Gilead Sciences, Inc. for 111 Days on average.
| DBA | GILD | |
|---|---|---|
Market Cap | $1.32B | $182.40B |
Volume | 771,657 | 4,469,821 |
52-Week High | $29.49 | $155.80 |
52-Week Low | $25.44 | $116.74 |
Typical Hold Time | 24 Days | 111 Days |
Sector | — | Health |
Enterprise Value | — | $205.46B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBA (Invesco DB Agriculture Fund ETF) trades at $28.42, down 0.25% on the day, with a bearish technical signal from moving averages but neutral oscillators. The fund has returned 12.4% year-to-date, closely tracking the S&P 500, supported by agricultural commodity strength from weather risks and geopolitical tensions. Recent news highlights DBA's consolidation near all-time highs with a 3.25% yield, though it faces a high expense ratio of 0.85%.
Outlook remains mixed with bullish agricultural trends from El Niño and demand catalysts balanced by sector volatility and expense concerns. Key risks include commodity price swings and geopolitical developments, while institutional sentiment leans neutral with a Hold rating from analysts citing momentum versus cost trade-offs.
Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.
Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Invesco DB Agriculture Fund
The index, which is comprised of one or more underlying commodities ("index commodities"), is intended to reflect the agricultural sector. The fund pursues its investment objective by investing in a portfolio of exchange-traded futures.
Read more on DBA →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
